ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types

Nature Communications

Volumn 7, Issue , 2016, Pages

  Lehmann, Waltraut ^a,b   Mossmann, Dirk ^b   Kleemann, Julia ^c   Mock, Kerstin ^a,b   Meisinger, Chris ^b   Brummer, Tilman ^b   Herr, Ricarda ^b   Brabletz, Simone ^c   Stemmler, Marc P ^c   Brabletz, Thomas ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR YAP1; TRANSCRIPTION FACTOR ZEB1; HOMEODOMAIN PROTEIN; MESSENGER RNA; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN; ZEB1 PROTEIN, HUMAN;

AGGRESSION; CANCER; GENE EXPRESSION; MOTILITY; SURVIVAL;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE; HUMAN; HUMAN CELL; PREDICTOR VARIABLE; PROTEIN INTERACTION; RISK; SURVIVAL; THERAPY RESISTANCE; BREAST TUMOR; CHROMATIN IMMUNOPRECIPITATION; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; MCF-7 CELL LINE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEK293 CELLS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO TECHNIQUES; MCF-7 CELLS; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84958555092     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10498     Document Type: Article

References (68)

1. Cho, R. W., Clarke, M. F. Recent advances in cancer stem cells. Curr. Opin. Genet. Dev. 18, 48-53 (2008).
2. Clevers, H. The cancer stem cell: premises, promises and challenges. Nat. Med. 17, 313-319 (2011).
3. Polyak, K., Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273 (2009).
4. Puisieux, A., Brabletz, T., Caramel, J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell. Biol. 16, 488-494 (2014).
5. Thiery, J. P., Acloque, H., Huang, R. Y., Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
6. Sánchez-Tilló, E. et al. Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am. J. Cancer Res. 1, 897-912 (2011).
7. Zhang, P., Sun, Y., Ma, L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 14, 481-487 (2015).
8. Bronsert, P. et al. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer. Surgery 156, 97-108 (2014).
9. Karihtala, P. et al. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast. Cancer Res. Treat. 138, 81-90 (2013).
10. Liu, Y. et al. Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis. Nat. Commun. 5, 5660 (2014).
11. Brabletz, S. et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 30, 770-782 (2011).
12. Giordano, A. et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol. Cancer Ther. 11, 2526-2534 (2012).
13. Vandewalle, C., Van Roy, F., Berx, G. The role of the ZEB family of transcription factors in development and disease. Cell. Mol. Life Sci. 66, 773-787 (2009).
14. Hu, F. et al. dEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Biochim. Biophys. Acta 1809, 200-210 2011.
15. Rhim, Andrew  . D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
16. Spaderna, S. et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 68, 537-544 (2008).
17. Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487-1495 (2009).
18. Shimono, Y. et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603 (2009).
19. Buck, E. et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther. 6, 532-541 (2007).
20. Singh, A., Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010).
21. Zhang, P. et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat. Cell Biol. 16, 864-875 (2014).
22. Brabletz, T. To differentiate or not-routes towards metastasis. Nat. Rev. Cancer 12, 425-436 (2012).
23. Chaffer, C. L.,Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559-1564 (2011).
24. Cordenonsi, M. et al. The hippo transducer TAZ confers cancer stem cellrelated traits on breast cancer cells. Cell 147, 759-772 (2011).
25. Harvey, K. F., Zhang, X., Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246-257 (2013).
26. Moroishi, T., Hansen, C. G., Guan, K.-L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 15, 73-79 (2015).
27. Hiemer, S. E., Szymaniak, A. D., Varelas, X. The transcriptional regulators TAZ and YAP direct transforming growth factor b-induced tumorigenic phenotypes in breast cancer cells. J. Biol. Chem. 289, 13461-13474 (2014).
28. Lamar, J. M. et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc. Natl Acad. Sci. USA 109, E2441-E2450 (2012).
29. Piccolo, S., Dupont, S., Cordenonsi, M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol. Rev. 94, 1287-1312 (2014).
30. Hiemer, S. E., Varelas, X. Stem cell regulation by the Hippo pathway. Biochim. Biophys. Acta 1830, 2323-2334 2013.
31. Wang, Z. et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl Acad. Sci. USA 111, E89-E98 (2014).
32. Rhodes, L. et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast. Cancer Res. Treat. 145, 593-604 (2014).
33. Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
34. Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68 (2010).
35. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
36. Lai, D., Ho, K. C., Hao, Y., Yang, X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 71, 2728-2738 (2011).
37. Wang, M.-Y. et al. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 69, 3482-3491 (2009).
38. Xie, D., Nakachi, K., Wang, H., Elashoff, R., Koeffler, H. P. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 61, 8917-8923 (2001).
39. Varelas, X. et al. The crumbs complex couples cell density sensing to hippodependent control of the TGF-b-SMAD pathway. Dev. Cell 19, 831-844 (2010).
40. Aigner, K. et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26, 6979-6988 (2007).
41. Oka, T., Mazack, V., Sudol, M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J. Biol. Chem. 283, 27534-27546 (2008).
42. Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747-2761 (2007).
43. Diepenbruck, M. et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition. J. Cell Sci. 127, 1523-1536 (2014).
44. Lei, Q.-Y. et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the Hippo pathway. Mol. Cell. Biol. 28, 2426-2436 (2008).
45. Liu, Y. et al. Taz-tead1 links cell-cell contact to zeb1 expression, proliferation, and dedifferentiation in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 51, 3372-3378 (2010).
46. Fujii, M. et al. TGF-b synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J. Exp. Med. 209, 479-494 (2012).
47. Xu, M. Z. et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 30, 1229-1240 (2011).
48. Györffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725-731 (2010).
49. Brabletz, S., Brabletz, T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep. 11, 670-677 (2010).
50. Paccez, J. D., Vogelsang, M., Parker, M. I., Zerbini, L. F. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int. J. Cancer 134, 1024-1033 (2014).
51. Zhao, B. et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22, 1962-1971 (2008).
52. Gjerdrum, C. et al. Axl is an essential epithelial-to-mesenchymal transitioninduced regulator of breast cancer metastasis and patient survival. Proc. Natl Acad. Sci. USA 107, 1124-1129 (2010).
53. Saglam, O. et al. Matricellular protein CCN1 (CYR61) expression is associated with high-grade ductal carcinoma in situ. Hum. Pathol. 45, 1269-1275 (2014).
54. Gheldof, A., Hulpiau, P., van Roy, F., De Craene, B., Berx, G. Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cell. Mol. Life Sci. 69, 2527-2541 (2012).
55. Zanconato, F. et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat. Cell Biol. 17, 1218-1227 (2015).
56. Postigo, A. A., Depp, J. L., Taylor, J. J., Kroll, K. L. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J. 22, 2453-2462 (2003).
57. Sanchez-Tillo, E. et al. ZEB1 and TCF4 reciprocally modulate their transcriptional activities to regulate Wnt target gene expression. Oncogene 34, 5760-5770 (2015).
58. Varelas, X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 141, 1614-1626 (2014).
59. Vlug, E. et al. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol. 36, 375-384 (2013).
60. Wang, X., Su, L., Ou, Q. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur. J. Cancer 48, 1227-1234 (2012).
61. Yuan, M. et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ. 15, 1752-1759 (2008).
62. Zhang, K. et al. Lats2 kinase potentiates Snail1 activity by promoting nuclear retention upon phosphorylation. EMBO J. 31, 29-43 (2012).
63. Röring, M. et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signallings. EMBO J. 31, 2629-2647 (2012).
64. Marotta, L. L. C. et al. The JAK2/STAT3 signaling pathway is required for growth of CD44\+CD24-stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121, 2723-2735.
65. Mootha, V. K. et al. PGC-1[alpha]-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
66. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
67. Vannier, C., Mock, K., Brabletz, T., Driever, W. Zeb1 regulates E-cadherin and Epcam (epithelial cell adhesion molecule) expression to control cell behavior in early zebrafish development. J. Biol. Chem. 288, 18643-18659 (2013).
68. Fujii, M. et al. TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J. Exp. Med. 209, 479-494 (2012).